Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1995-08-18
1997-03-25
Chang, Ceila
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514212, 514255, 514364, 514374, 540603, 544369, 546208, 548134, 548135, 548230, A61K 31445, A61K 3142, C07D26324, C07D41312
Patent
active
056145357
ABSTRACT:
Compounds of the formula I ##STR1## in which R.sup.1 and X have the meanings herein defined, their physiologically unobjectionable salts and/or solvates inhibit the binding of fibrinogen to the corresponding receptor and can be employed for the treatment of thromboses, osteoporosis, tumoral diseases, apoplexy, cardiac infarction, inflammations, arteriosclerosis and osteolytic disorders.
REFERENCES:
patent: 2437388 (1948-03-01), Homeyer et al.
patent: 4866182 (1989-09-01), Schnettler et al.
patent: 5356918 (1994-10-01), Ishihara et al.
Vajta et al. "Reversed-phase high performance liquid chromatographic separation of 14C-labeled toloxatone and tis metabolites" CA 102:5518 1984.
Born, Nature, 4832:927-929 (1962).
Smith et al., J. Biol. Chem., 265:12267-12271 (1990).
Bernotat-Danielowski Sabine
Gante Joachim
Juraszyk Horst
Melzer Guido
Wurziger Hanns
Chang Ceila
Merck Patent Gesellschaft mit beschrankter Haftung
LandOfFree
Adhesion receptor antagonists does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Adhesion receptor antagonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Adhesion receptor antagonists will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2203734